CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing ...

and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer Doudna – said it is focusing on NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex ...

NTLA-2002 para el tratamiento del angioedema hereditario; y NTLA-3001 para la enfermedad pulmonar asociada a la deficiencia de alfa-1 antitripsina. También se centra en programas que comprenden ...

Intellia Therapeutics, Inc. (NTLA) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...

List of all 2002 amavasya dates and exact start time and end time of Amavasya tithi in 2002. The timings below is for Boydton, United States. View Today's tithi → Next Krishna Paksha Amavasya tithi is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cuál es la situación actual de las medias móviles de NTLA ahora mismo? Las medias móviles de Intellia Therapeutics Inc indican una previsión de Neutral, según las medias móviles que van ...